Paclitaxel CAS#33069-62-4
Paclitaxel, a monomeric diterpene compound derived from the bark of Taxus plants, is a complex secondary metabolite. It stands as the sole known agent capable of inducing microtubule polymerization and stabilizing the polymerized microtubules. Isotope tracing studies have demonstrated that paclitaxel specifically binds to polymerized microtubules without interacting with unpolymerized tubulin dimers. Upon cellular exposure to paclitaxel, significant intracellular microtubule accumulation occurs. This buildup disrupts multiple cellular functions, most notably halting cell division during the mitotic phase and impeding normal cell proliferation. Clinical trials spanning phases II and III have established paclitaxel’s primary utility in treating ovarian and breast cancer. It also exhibits therapeutic potential against lung cancer, colorectal cancer, melanoma, head and neck cancer, lymphoma, and brain tumors.
Paclitaxel Chemical Parameters
Melting point | 213 °C (dec.)(lit.) |
alpha | D20 -49° (methanol) |
Boiling point | 774.66°C (rough estimate) |
density | 0.2 |
refractive index | -49 ° (C=1, MeOH) |
Fp | 9℃ |
storage temp. | 2-8°C |
solubility | methanol: 50 mg/mL, clear, colorless |
form | |
pka | 11.90±0.20(Predicted) |
color | white |
Water Solubility | 0.3mg/L(37 ºC) |
λmax | 227nm(MeOH)(lit.) |
Merck | 146982 |
BRN | 1420457 |
Stability: | Stable. Incompatible with strong oxidizing agents. Combustible. |
InChIKey | RCINICONZNJXQF-MZXODVADSA-N |
LogP | 3.950 (est) |
CAS DataBase Reference | 33069-62-4(CAS DataBase Reference) |
EPA Substance Registry System | Paclitaxel (33069-62-4) |
Safety Information | |
Hazard Codes | Xn |
Risk Statements | 37/38-41-42/43-62-68-40-48-20/21/22-68/20/21/22 |
Safety Statements | 22-26-36/37/39-45 |
RIDADR | 1544 |
WGK Germany | 3 |
RTECS | DA8340700 |
F | 45951 |
HazardClass | 6.1(b) |
PackingGroup | III |
HS Code | 29329990 |
Hazardous Substances Data | 33069-62-4(Hazardous Substances Data) |
Toxicity | LD50 intraperitoneal in mouse: 128mg/kg |
Paclitaxel CAS#33069-62-4 Application
This is a broad-spectrum anti-tumor agent derived from herbal sources, primarily indicated for the treatment of metastatic breast cancer and metastatic ovarian cancer, among other malignancies.As an effective anti-microtubule medication, it binds to the N-terminal domain of β-tubulin. It facilitates the assembly of highly stable microtubule structures, confers resistance to depolymerization, and arrests normal cell division at the G2/M phase of the cell cycle.By promoting tubulin polymerization to suppress depolymerization, the drug maintains tubulin stability and inhibits cellular mitosis. It exerts activity against human endothelial cells with an IC50 value of 0.1 pM.
Factory Show
As an ISO-certified chemical exporter with 15 years of professional experience, we leverage leading production technology, advanced equipment, and a professional team to provide high-quality chemical raw materials to over 2,000 companies worldwide. Our products are widely used in pharmaceuticals, agriculture, food manufacturing, and industrial production, with business spanning six continents. We are committed to providing reliable supply chain support and solutions to customers across various industries.
